Continuous Bioprocessing Market is poised to register a CAGR of 23% during the forecast period 2022 to 2028.

The rising insistence for biopharmaceutical products, development of advanced technologies pertaining to continuous bioprocessing, bolstered support from government for manufacturing biopharmaceuticals are some of the driving factors contributing to the growth of the market. The consistent production of biopharmaceuticals on a commercial and clinical level with the use of flexible facilities is called continuous bioprocessing.   

The continuous bioprocessing market growth is primarily driven by increased development of novel technologies, rising insistence for biopharmaceuticals, increased support from the government for manufacturing biopharmaceuticals. There has been a significant escalation in the occurrence of chronic disorders across the world. As per the American Pharmaceutical Review, the insistence for antibody products has escalated and with the biologic license application, the antibody products account for over 65% of all the biopharmaceutical products. Furthermore, as per the journal, over 80% of the products are in phase 3 of the development stage while over 90% of products are currently in phase 1 and phase 2 of development.

Moreover, with complexities occurring in clinical trials, the financial assistance provided by the government for research and development activities has increased significantly. For instance, the government of India announced the ‘Pharma Vision 2020’ in 2018 and this aims at reducing the time required for approving new sites, thereby escalating the capacity of producing biopharmaceuticals. Additionally, the government has decided to completely favour FDI for the pharmaceutical industry resulting in the rise of collaborations between the government and the pharmaceutical giants. Furthermore, The National Institute of Health of the United States partnered with over 10 biopharma companies in 2017 to announce the ‘Partnership for Accelerating Cancer Therapies’, which is a private-public research collaboration set for five years. This collaboration shall help in developing immunotherapies for cancer with a total investment of over USD 200 million. Moreover, Japan’s Ministry of Health, Labour and Welfare in 2015 announced the ‘Sakigake’ scheme that aimed at accelerating the launch time for novel drugs.              

However, high contamination risks pertaining to continuous processing, operational complexities related to continuous processing and a lack of professionals that work into bioprocessing are some of the factors restraining the market growth.

Market Segmentation:

By Product
• Filtration Systems and Consumables
• Chromatography Systems and Consumables
• Bioreactors
• Sterilizers
• Centrifuges
• Incubators and Shakers
• Mixing Systems
• Cell Culture Media, Buffers, and Reagents
• Other instruments and consumables

By Application
• Commercial
  o Vaccines
  o mAb production
  o Recombinant Protein Production
  o Cell and Gene Therapy Production
• R&D

By End User
• Pharmaceutical and Biotechnology Companies
• Contract Development and Manufacturing Organizations and Contract Research Organizations
• Academic and Research Institutes

By Region
• North America
• Asia-Pacific
• Latin America
• Middle East and Africa

Regional Analysis:

The North America region is expected to dominate the market during the forecast period owing to a strong presence of prominent market players in the region and the rising support by the government by assigning funds for research and development of continuous bioprocessing. However, the Asia Pacific region is predicted to grow with a substantial rate over the forecasted timeframe owing to a rise in the occurrence of chronic disorders, increased emphasis of the government in improving the biopharmaceutical industry. Additionally, important business expansions by key market players in the region shall augment the market growth.

Competitive Landscape:

Some of the prominent players of the market are GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc., Sartorius AG, Repligen Corporation, Eppendorf AG, 3M Company, Applikon Biotechnology B.V.

FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

Objectives of the Study:

  • To provide with an exhaustive analysis on the global continuous bioprocessing market by product, by application, by end user and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions 

Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics